Typ-2-Diabetes – nach der Diagnose

Sie wurden mit Diabetes Typ 2 diagnostiziert. Wie geht es nun für Sie weiter? Was wird sich verändern? Sie werden in der kommenden Zeit viele Informationen und Schulungen erhalten, um Ihr Leben mit der Erkrankung bestens zu meistern. Betrachten Sie die folgenden Hinweise als kleine Einführung.

Deximed – Deutsche Experteninformation Medizin

"Deximed ist für mich eine große Hilfe, um im Praxisalltag schnell aktuelles Wissen zur Therapie oder Diagnostik nachschlagen zu können. Die übersichtliche Struktur ermöglicht es, sogar im Patientenkontakt rasch etwas nachzulesen." - PD Dr. med. Guido Schmiermann, Facharzt für Allgemeinmedizin, Bremen

Deximed ist ein unabhängiges Arztinformationssystem mit Fokussierung auf die primärärztliche Versorgung. Evidenzbasierte und regelmäßig aktualisierte Artikel zu allen medizinischen Gebieten zeichnen Deximed aus.

Mehr erfahren

Das sollten Sie wissen:

  • Typ-2-Diabetes ist eine chronische Erkrankung. Das bedeutet, dass die Krankheit nicht zu heilen ist. Es ist daher wichtig zu lernen, mit dieser Erkrankung richtig zu leben. Wird der Diabetes nicht behandelt, so führt die erhöhte Menge an Zucker im Blut zu Folgeschäden. Außerdem fühlen Sie sich schlapp und leistungsgemindert. Es gibt aber viele wirkungsvolle Therapien und Maßnahmen, die Sie selber ergreifen können, damit es Ihnen besser geht. Spätfolgen werden dadurch ebenfalls verringert.
  • Als Erstes müssen Sie Ihre Ernährung umstellen. Versuchen Sie weniger Zucker, fett- und kalorienreiche Nahrungsmittel zu sich zu nehmen. Es gibt keinen Grund, auf spezielle Diabetikerkost umzusteigen. Gesundheitsfördernd ist außerdem ausreichend Bewegung. Sollten Sie nicht regelmäßig Sport treiben, beginnen Sie langsam mit der sportlichen Betätigung und integrieren Sie diese nun in Ihren Alltag.
  • Durch eine ausgewogene Ernährung und sportliche Betätigung sollten Sie im Stande sein ein eventuelles Übergewicht zu bekämpfen. Denn dieses hat nicht nur negative Auswirkungen auf den Typ-2-Diabetes, sondern ist auch ein Risikofaktor für weitere Erkrankungen.
  • Sie sollten mit dem Rauchen aufhören. 
  • Mithilfe einer Blutuntersuchung kann die Veränderung des Zuckerspiegels in Ihrem Blut (Blutzucker) kontrolliert werden. In Ihrem Blut kann ebenfalls der durchschnittliche Blutzuckerspiegel der letzten sechs bis acht Wochen festgestellt werden (Glykohämoglobin bzw. HbA1c). Je nachdem, wie hoch Ihr Blutzuckerwert ist, müssen Sie früher oder später Medikamente in Tablettenform nehmen, mit denen Sie den Blutzuckerspiegel senken können. Weitere Informationen erhalten Sie von Ihrem Arzt.
  • Es ist wichtig, dass Sie regelmäßig zu Kontrollen zu Ihrem Arzt gehen. Der Blutzuckerspiegel muss gut eingestellt sein und sollte nicht zu großen Schwankunge unterliegen. Desweiteren kommen noch Kontrolluntersuchungen weiterer Organe hinzu, die eventuell durch die Erkrankung in Mitleidenschaft gezogen werden können, wenn diese nicht gut behandelt ist.

Weitere Informationen

Autoren

  • Natalie Anasiewicz, Ärztin, Freiburg

Literatur

Dieser Artikel basiert auf dem Fachartikel Typ-2-Diabetes. Nachfolgend finden Sie die Literaturliste aus diesem Dokument.

  1. Lohnstein M, Eras J, Hammerbacher C. Der Prüfungsguide Allgemeinmedizin - Aktualisierte und erweiterte 3. Auflage. Augsburg: Wißner-Verlag, 2018.
  2. Robert-Koch-Institut (RKI). Faktenblatt zu DEGS1. Prävalenz von Diabetes mellitus. 2005. Gesundheitsberichterstattung des Bundes. www.rki.de
  3. Deutsche Diabeteshilfe und DDG. Deutscher Gesundheitsbericht Diabetes 2017. www.diabetesde.org
  4. Heidemann C, Du Y, Schubert I, Rathmann W, Scheidt-Nave C. Prävalenz und zeitliche Entwicklung des bekannten Diabetes mellitus. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl 2013, 56:668–677 edoc.rki.de
  5. NCD Risk factor collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016;387:1513-30 thelancet.com
  6. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P,Wasem J, JöckelK-H: Impact of four different definitions used for assessment of theprevalence of metabolic syndrome in a primary health care setting. The German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2007; 6: 22. www.ncbi.nlm.nih.gov
  7. Diabetes-Deutschland.de. 2004. www.diabetes-deutschland.de
  8. World Health Organization (WHO). Diabetes Programme. www.who.int
  9. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015; 314: 1021-9. doi: 10.1001/jama.2015.10029. DOI
  10. Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991; 338: 774 - 8. PubMed
  11. Birkeland KI, Kilhovd B, Thorsby P et al. Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile. Diabet Med 2003; 20: 37-45. PubMed
  12. Basu S, Yoffe P, Hills N, Lustig RH. The relationship of sugar to population-level diabetes prevalence: An economic analysis of repeated cross-sectional data. PLOS One 2013. doi:10.1371/journal.pone.0057873 DOI
  13. Rathmann W, Scheidt-Nave C, Roden M, Herder C. Typ-2-Diabetes: Prävalenz und Relevanz angeborener und erworbener Faktoren für die Prädiktion. Dtsch Arztebl Int 2013; 110(19): 331–7 edoc.rki.de
  14. Hauner H, Bramlage P, Lösch C, Schunkert H, Wasem J, Jöckel KH, Moebus S. Übergewicht, Adipositas und erhöhter Taillenumfang. Regionale Prävalenzunterschiede in der hausärztlichen Versorgung. Dtsch Arztebl 2008; 105(48): 827-33; DOI: 10.3238/arztebl.2008.0827. www.aerzteblatt.de
  15. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA et al. Weight as a risk faktor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501-13 www.ncbi.nlm.nih.gov
  16. Informationen für Patienten und Fachleute aus erster Hand. Schwerpunkt: Endokrinologie / Diabetologie. MODY-Diabetes. Professor Dr. med. W.A. Scherbaum. Direktor der Klinik für Endokrinologie, Diabetologie und Rheumatologie des Universitätsklinikums Düsseldorf. www.mody-diabetes.de
  17. Deutsche Gesellschaft für Allgemeinmedizin (DEGAM). Leitlinien. Anwenderversion zur NVL Typ-2-Diabetes: Therapie. Stand 2013. www.degam.de
  18. Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015 Jul;19(57):1-210. www.ncbi.nlm.nih.gov
  19. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes care 1999; 22: 307-13. www.ncbi.nlm.nih.gov
  20. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-eff ectiveness analysis. Lancet 2010; 375: 1365-74 www.ncbi.nlm.nih.gov
  21. Selph S, Dana T, Blazina I, et al. Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. Ann Int Med 2015; 162: 765-76. doi:10.7326/M14-2221 annals.org
  22. Vijan S, Hofer TP, Hayward RA. Cost-Utility Analysis of Screening Intervals for Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus. JAMA 2000; 283:889-896. jama.jamanetwork.com
  23. Programm für Nationale VersorgungsLeitlinien. BÄK, KBV, AWMF. Nationale VersorgungsLeitlinie (NVL) Diabetes. www.leitlinien.de
  24. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 Diabetes: A patient-centered approach. Diabetes Care 2012; 35: 1364-79. doi: 10.2337/dc12-0413 DOI
  25. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352: i717. doi:10.1136/bmj.i717 DOI
  26. Deutsches Ärzteblatt. ACCORD und ADVANCE-Studie: Wie gefährlich ist die aggressive HbA1c-Reduktion bei Typ-II-Diabetes mellitus? 9. Juni 2008. www.aerzteblatt.de
  27. arznei-telegramm. ACCORD-STUDIE - Therapieempfehlungen bei Typ-2-Diabetes auf dem Prüfstand. a-t 2010; 41: 35-7. www.arznei-telegramm.de
  28. Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017 Jun 8; 6: CD010137. doi:10.1002/14651858.CD010137.pub2 DOI
  29. Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med 2018. doi:10.7326/M17-0939 DOI
  30. The ACCORD study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; : 10.1056/NEJMoa1001286. www.nejm.org
  31. Sussman JB, Kent DM, Nelson JP, Hayward RA. Improving diabetes prevention with benefit based tailored treatment: Risk based analysis of Diabetes Prevention Program. BMJ 2015; 350:h454 www.bmj.com
  32. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91. www.nejm.org
  33. Coppell K, Kataoka M, Williams SM, et al. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment—Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. BMJ 2010; 341: c3337. BMJ (DOI)
  34. Gregg E, Chen H, Wagenknecht L, Clark J, Delahanty L, et al. Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. JAMA 2012 Dec 19; 308(23): 2489–2496. doi:10.1001/jama.2012.67929 DOI
  35. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2017 Dec 4; pii: S0140-6736(17)33102-1: Epub ahead of print. pmid:29221645 PubMed
  36. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013 ; 369: 145-54. pmid:23796131 PubMed
  37. Lee SF, Pei D, Chi MJ, et al. An investigation and comparison of the effectiveness of different exercise programmes in improving glucose metabolism and pancreatic beta cell function of type 2 diabetes patients. Int J Clin Pract. 2015. PMID: 26119968 PubMed
  38. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93. www.ncbi.nlm.nih.gov
  39. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes. Ann Intern Med 2016. doi:10.7326/M15-2650 annals.org
  40. Lindholm LH. Major benefits from cholesterol-lowering in patients with diabetes. Lancet 2003; 361: 2000-1. PubMed
  41. Renders CM, Valk GD, Griffin SJ, Wagner E, van Eijk JT, Assendelft WJJ. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001481. DOI: 10.1002/14651858.CD001481. DOI
  42. Davies MJ, Heller S, Skinner TC, et al, for the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008; 336: 491-5. www.ncbi.nlm.nih.gov
  43. Nield L, Moore H, Hooper L, Cruickshank K, Vyas A, Whittaker V, Summerbell CD. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004097. DOI: 10.1002/14651858.CD004097.pub4. DOI
  44. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575 PubMed
  45. Deutsche Gesellschaft für Ernährung (DGE). Evidenzbasierte Ernährungsempfehlungen für die Behandlung und Prävention des Diabetes mellitus. Stand 2005. www.dge.de
  46. Deutsche Gesellschaft für Ernährung (DGE). Evidenzbasierte Leitlinie: Kohlenhydratzufuhr und Prävention ausgewählter ernährungsmitbedingter Krankheiten (2011). www.dge.de
  47. Deutsche Gesellschaft für Ernährung (DGE). Evidenzbasierte Leitlinie: „Fettzufuhr und Prävention ausgewählter ernährungsmitbedingter Krankheiten“, 2. Version 2015. www.dge.de
  48. Avery L, Flynn D, van Wersch A, et al. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care 2012; 35: 2681-9. PubMed
  49. Schulze zur Wiesch C, Lautenbach A, Sauer N, Mann O, Aberle J. Adipositas-Steuerung außer Kontrolle. Hamburger Ärzteblatt 07/08 2016. www.aerztekammer-hamburg.org
  50. Deutsche Gesellschaft für Ernährung (DGE). Pressemitteilung DGE aktuell 04/2015. DGE empfiehlt: Auf Fettmenge und -qualität achten. www.dge.de
  51. Jenkins DJA, Kendall CWC, McKeown-Eyssen G, et al. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes. JAMA 2008; 300: 2742-53. jamanetwork.com
  52. Lycett D, Nichols L, Ryan R, et al. The association between smoking cessation and glycaemic control in patients with type 2 diabetes: a THIN database cohort study. Lancet Diabetes Endocrinol 2015; 6: 423-30. doi:10.1016/S2213-8587(15)00082-0 DOI
  53. Deutsche Diabetes Gesellschaft (DDG). Evidenzbasierte Leitlinien. Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. www.deutsche-diabetes-gesellschaft.de
  54. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 2016; Suppl. 1: S52-S59. doi:10.2337/dc16-S010 DOI
  55. Xu T, Brandmaier S, Messias AC, et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Dia Care 2015. doi:10.2337/dc15-0658 DOI
  56. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497. www.ncbi.nlm.nih.gov
  57. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8:e71583. journals.plos.org
  58. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340: c2181. BMJ (DOI)
  59. Liu Q, Li S, Quan H, et al. Vitamin B12 status in metformin treated patients: systematic review. PLoS One. 2014 ;9(6):e100379. PMID: 24959880 PubMed
  60. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010; 33: 156-61. www.ncbi.nlm.nih.gov
  61. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD002967. DOI: 10.1002/14651858.CD002967.pub4. DOI
  62. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312: 2668-75. doi:10.1001/jama.2014.15298 DOI
  63. Phung OJ, Schwartzman E, Allen RW, et al . Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013; 30: 1160-71. doi:10.1111/dme.12232. onlinelibrary.wiley.com
  64. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2012. www.ncbi.nlm.nih.gov
  65. Liu SC, Tu YK, Chien MN, et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. . Diabetes Obes Metab 2012; 14: 810-20. PubMed
  66. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-5. PMID: 17277036 PubMed
  67. Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, Rutten GEHM, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD003639. DOI: 10.1002/14651858.CD003639.pub2. DOI
  68. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7. www.ncbi.nlm.nih.gov
  69. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356. www.nejm.org
  70. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: doi:10.1001/jama.2010.920. DOI
  71. Viberti G, Lachin J, Holman R, et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med 2006; 23: 1289-94. PubMed
  72. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645. www.bmj.com
  73. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: a systematic review and meta-analysis. BMJ 2012; 344: e1369. BMJ (DOI)
  74. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-61. PubMed
  75. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014; 15: 348 :g2366. doi: 10.1136/bmj.g2366. DOI
  76. Green JB, Betehel MA, Armsrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015. doi: 10.1056/NEJMoa1501352 DOI
  77. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N EnglJ Med 2013. doi: 10.1056/NEJMoa1307684 DOI
  78. Faillie JL, Filion KB, Patenaude V, et al. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 379-85. doi:10.1111/dom.12431 DOI
  79. FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. FDA Drug Safety Communication, Aug. 2015. www.fda.gov
  80. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013. PMID: 24320621 PubMed
  81. Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014 ;30(3):204-21. doi: 10.1002/dmrr.2479. www.ncbi.nlm.nih.gov
  82. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2013. onlinelibrary.wiley.com
  83. Rosenstock J, Chuck L, Gonzalez-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 2016. pmid: 26786577 PubMed
  84. arznei-telegramm: Diabetische Ketoazidose unter SGLT-2-Hemmern...daran denken, Triggerfaktoren beachten. a-t 2018; Jg. 49, Nr. 4 www.arznei-telegramm.de
  85. a-t: Me too: SGLT-2-Hemmer Ertugliflozin (in: Steglujan). arznei-telegramm 2018; Jg 49, Nr. 6 www.arznei-telegramm.de
  86. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015. doi:10.1056/NEJMoa1504720 DOI
  87. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016. PMID: 26819227 PubMed
  88. Arznei-Telegramm (AT). EMPA-REG-OUTCOME-STUDIE MIT SGLT- 2-HEMMER EMPAGLIFLOZIN (JARDIANCE)… die große Frage: ein Durchbruch? a-t 2015; 46: 95-7. www.arznei-telegramm.de
  89. Arznei-Telegramm (AT). EMPA-REG-OUTCOME-STUDIE MIT EMPAGLIFLOZIN (JARDIANCE)… Zweifel an einwandfreier Durchführung verstärkt. a-t 2016; 47: 65-6. www.arznei-telegramm.de
  90. Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018; 363: k4365. pmid:30429124 www.ncbi.nlm.nih.gov
  91. GBA. Dapagliflozin (neue wissenschaftliche Erkenntnisse), Nr. 610, A17-65, Version 1.0, Stand: 28.03.2018 www.akdae.de
  92. Lund SS, Tarnow L, Frandsen M, et al. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 2009; 339: b4324. BMJ (DOI)
  93. EMA: Investigation into GLP-1 based diabetes therapies concluded, 2013-07-26 www.ema.europa.eu
  94. Arznei-Telegramm (AT). LEADER-STUDIE MIT LIRAGLUTID (VICTOZA)… erste Positivdaten zu einem GLP-1-Agonisten bei Typ-2-Diabetes (Langversion). e-at. 7/2016 (online veröffentlicht am 8. Juli 2016). www.arznei-telegramm.de
  95. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-22. pmid:27295427 PubMed
  96. Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377(13): 1228-1239. pmid:28910237 PubMed
  97. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. www.ncbi.nlm.nih.gov
  98. Madsbad S, Kielgast U, Asmar M et al. An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13: 394-407. PubMed
  99. Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014; 31: 176-84. PMID: 24117597 PubMed
  100. Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-labeled randomised trial. Lancet 2010; 375: 2234-43. PubMed
  101. D'Alessio D., Häring H.-U., Charbonnel B, et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes, Obesity and Metabolism 2015; 17: 170-8. doi:10.1111/dom.12406 DOI
  102. Eng C, Kramer CK, Zinman B, Retnakaran R. Glukagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014. www.ncbi.nlm.nih.gov
  103. Lind M, Hirsch IB, Tuomielehto J, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial) . BMJ 2015; 351: h5364. doi:10.1136/bmj.h5364 DOI
  104. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. PubMed
  105. Lipska K, Parker M, Moffet H, Huang E, Karter A. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2018;320:53-62. www.ncbi.nlm.nih.gov
  106. Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care 2015. pmid:26253730 PubMed
  107. IQWIG. (A05-03). 2009. Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. www.iqwig.de
  108. IQWIG. (A05-04). 2006. Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. www.iqwig.de
  109. Gemeinsamer Bundesausschuss. G-BA-Beschluss zu Insulinanaloga. März 2010. www.g-ba.de
  110. IQWIG. 2014. Zusatznutzen von Insulin degludec ist nicht belegt. www.iqwig.de
  111. Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. . Diabetes Obes Metab 2013 Feb 19 . pmid:23421331 PubMed
  112. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy om complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-47. www.nejm.org
  113. Muller N, Frank T, Kloos C, et al. Randomized Crossover Study to Examine the Necessity of an Injection-to-Meal Interval in Patients With Type 2 Diabetes Mellitus and Human Insulin. Diabetes Care 2013 Jan 22. PMID: 23340895. PubMed
  114. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-76. www.nejm.org
  115. McBrien K, Rabi DM, Campbell N, et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis.. . Arch Intern Med 2012 Aug 6:1-8 . pmid:PMID: 22868819 www.ncbi.nlm.nih.gov
  116. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013 Oct 30;10:CD008277 Cochrane (DOI)
  117. Margolis KL, Palermo L, Vittinghoff E, et al. Intensive Blood Pressure Control, Falls, and Fractures in Patients with Type 2 Diabetes: The ACCORD Trial. J Gen Intern Med. 2014 Aug 16. PMID: 25127725 www.ncbi.nlm.nih.gov
  118. Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord. 2014;14:148. doi: 10.1186/1471-2261-14-148 DOI
  119. Handlungsleitlinie-Arzneimittelkomission der Deutschen Ärzteschaft. Fettstoffwechselstörungen. 2012. www.akdae.de
  120. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004; 140:644-49. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American Colege of Physicians. Ann Intern Med 2004; 140: 650-8. www.ncbi.nlm.nih.gov
  121. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial . Lancet 2002; 360: 7-22. PubMed
  122. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96. PubMed
  123. De Berardis G, Sacco M, Strippoli G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531. www.ncbi.nlm.nih.gov
  124. Derosa G, Mugellini A, Pesce RM, et al. A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus. Cardiovasc Diabetol 2015;14(95 www.ncbi.nlm.nih.gov
  125. Arznei-Telegramm (AT). ASS ZUR PRIMÄRPRÄVENTION BEI ALLEN DIABETIKERN? a-t 2008; 39: 124-5. www.arznei-telegramm.de
  126. Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A Randomized controlled trial. JAMA 2008; 300: 2134-41. www.ncbi.nlm.nih.gov
  127. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. www.ncbi.nlm.nih.gov
  128. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Diabetes Care 2010; 33: 1395-1402. PubMed
  129. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-84. doi:10.1056/NEJMoa1211585 DOI
  130. Timmer JR, Ottervanger JP, de Boer MJ, et al. Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus: Results From the Primary Coronary Angioplasty vs Thrombolysis-2 Trial. Arch Intern Med 2007; 167: 1353-9. PubMed
  131. Deutsche Gesellschaft für Allgemeinmedizin (DEGAM). Leitlinie: Hausärztliche Risikoberatung zur kardiovaskulären Prävention. S3. Stand 2017 www.degam.de
  132. Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003556. DOI: 10.1002/14651858.CD003556.pub2. DOI
  133. Kranke P, Bennett MH, Martyn-St et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2015;6:CD004123. DOI:10.1002/14651858.CD004123.pub4 DOI
  134. Heller T, Blum M, Spraul M, Wolf G, Müller UA. Folgeerkrankungen des Diabetes mellitus in Deutschland: Prävalenzen in Deutschland. Dtsch Med Wochenschr 2014; 139: 786–91 www.thieme-connect.de
  135. Abholz HH, Egidi G, Zitterbart U. Prävalenz von Folgeerkrankungen und Nutzen der Glukosesenkung bei Diabetes mellitus Ty 2.Z Allg Med 2013; 91: 220-226 www.online-zfa.de
  136. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-33. www.ncbi.nlm.nih.gov
  137. Bangalore S, Fakheri R, Toklu B, Messerli FH Diabetes mellitus as a compelling indication for use of reninangiotensin system blockers: systematic review and meta-analysisof randomized trials. BMJ 2016;352:i438 BMJ (DOI)
  138. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360. BMJ (DOI)
  139. Strippoli GF, Craig MC, Scheana FP, Craig JC. Role of Blood Pressure Targets and Specific Antihypertensive Agents Used to Prevent Diabetic Nephropathy and Delay Its Progression. J Am Soc Nephrol 2006; 17(Suppl 2): S153-5. www.ncbi.nlm.nih.gov
  140. Bril V, England J, Franklin GM, et al. Evience-based guideline: Treatment of painful diabetic neuropathy. Neurology 2011; 76: 1. www.ncbi.nlm.nih.gov
  141. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000; 20: 449-58. PubMed
  142. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Syst Rev 2014; 4:CD007938. DOI: 10.1002/14651858.CD007938.pub3 DOI
  143. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013 ;11:CD010567. doi: 10.1002/14651858.CD010567.pub2 DOI
  144. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2005; 28: 2780-6. PubMed
  145. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-9. PubMed
  146. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. . Lancet 2012 Oct 3. pmid:23040422 PubMed
  147. Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in swedish obese subjects. N Engl J Med 2012; 367: 695-704. www.nejm.org
  148. Martínez-González MA, Fuente-Arrillaga C, Nunez-Cordoba JM et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study . BMJ 2008; 336: 1348-51. www.ncbi.nlm.nih.gov
  149. Koloverou E, Esposito K, Giugliano D, et al. The effect of Mediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136,846 participants. Metabolism. 2014 ;63(7):903-11. doi: 10.1016/j.metabol.2014.04.010 www.ncbi.nlm.nih.gov
  150. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334: 299. www.bmj.com
  151. Andreadis EA, Katsanou PM, Georgiopoulos DX, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects - The Carmos Study. Exp Clin Endocrinol Diabetes 2009 Apr;117(4):175-80. doi: 10.1055/s-0028-1087177. DOI
  152. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59. www.nejm.org
  153. Anderson RT, Narayan KM, Feeney P, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 2011; 34: 807-12. PubMed
  154. Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Med 1997; 24: 321 - 36. PubMed
  155. Deakin TA, McShane CE, Cade JE, Williams R. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD003417. DOI: 10.1002/14651858.CD003417.pub2. DOI
  156. The Origin Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012. pmid:22686415 PubMed
  157. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-15. doi: 10.1001/jama.2014.18574. www.ncbi.nlm.nih.gov
  158. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352; i717 www.bmj.com
  159. Olivarius NdF, Beck-Nielsen H, Andreasen AH et al. Randomised controlled trial of structured personal care of type 2 diabetes. BMJ 2001; 323: 970-5. www.ncbi.nlm.nih.gov
  160. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes mellitus. JAMA 1999; 281:2005-2012. www.ncbi.nlm.nih.gov
  161. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36: 376-82. PubMed
  162. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use intype 2 diabetes mellitus (Review). The Cochrane Library 2010, Issue 4. www.cochrane.org
  163. Nyirenda MJ, Sandeep T, Grant I et al. Severe acidosis in patients taking metformin - rapid reversal and survival despite high APACHE score. Diabet Med 2006; 23: 432-5. PubMed
  164. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-8. PubMed
  165. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22. PubMed
  166. Goto A, Arah OA, Goto M, et al. Severe hypoglycemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533. BMJ (DOI)
  167. Mason J, O`Keeffe C, McIntosh A, et al. A systemativ review of foot ulcer in patients with type 2 diabetes mellitus. I: Prevention. Diabet Med 1999; 16:801-12. PubMed
  168. RKI-Ratgeber für Ärzte: Staphylokokken-Erkrankungen, insbesondere Infektionen durch MRSA www.rki.de
  169. Carstensen B, Kristensen JK, Marcussen MM et al. The National Diabetes Register. Scand J Public Health 2011; 39(suppl 7): 58-61. www.ncbi.nlm.nih.gov
  170. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373:1720-1732 . doi:10.1056/NEJMoa1504347 DOI
  171. Robert-Koch-Institut (RKI). Gesundheitsberichterstattung des Bundes. Themenheft Diabetes mellitus. 2005.
  172. Dale AC, Vatten LJ, Nilsen TI et al. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 2008; 337: 1-6. www.ncbi.nlm.nih.gov
  173. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study . BMJ 2001; 322: 1389-93. PubMed
  174. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet 2000; 355: 253-9. PubMed
  175. Hayward RA, Reaven PD, Wiitala W, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 372: 2197-2206. doi:10.1056/NEJMoa1414266 DOI
  176. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Diabetes Care 2005; 28: 1510-17. PubMed
  177. O´Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336: 1174-7. British Medical Journal
  178. Deutsche Diabetes Gesellschaft (DDG). Diabetes und Straßenverkehr. AWMF-Leitlinie Nr. 057 - 026. S2e. Stand 2017. www.awmf.org